News | March 06, 2009

Study Suggests Referring Patients with Abnormal Stress Heart Rate Recovery for SPECT Imaging

Researchers at the Section of Cardiology, Department of Medicine, University of Chicago Hospitals said their findings, published in the March 1 issue of the American Journal of Cardiology, Vol. 103, Issue 5, suggest SPECT perfusion imaging should be conducted on patients who have abnormal heart rate recovery (HRR) on routine exercise treadmill testing.

Abnormal HRR after maximal exercise treadmill testing predicts adverse cardiac outcomes, although whether abnormal HRR on exercise treadmill testing should prompt further diagnostic cardiac testing is unknown. This prompted the research team to determine the prevalence of high-risk stress SPECT myocardial perfusion imaging (MPI) findings in patients with abnormal HRR.

A total of 509 men who had been referred for exercise stress MPI and were without other abnormal exercise treadmill testing findings (ischemic electrocardiographic changes or exercise treadmill testing - induced angina) were included in this study. Abnormal HRR was defined as a decrease in heart rate 12 beats at one minute after maximal exercise.

The study found 11 percent of the patients had abnormal HRR. Patients with abnormal HRR had significantly more mild or greater coronary heart disease, severe coronary heart disease, left ventricular dysfunction, and composite high-risk MPI findings compared with those without abnormal HRR. Researchers found on multivariate logistic regression analysis, abnormal HRR was found to be an independent predictor of mild or greater coronary heart disease with a 95 percent confidence interval, severe coronary heart disease, and composite high-risk MPI findings.

The study concluded abnormal HRR on exercise treadmill testing was associated with a high prevalence of abnormal and high-risk stress MPI findings, even in patients without other exercise treadmill testing findings that traditionally would prompt further testing.

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init